AVP Receptor V1a Double Nickase Plasmid (h): sc-401691-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- AVP Receptor V1a Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- AVP Receptor V1a Double Nickase Plasmid (h) and AVP Receptor V1a Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting AVPR1A. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: AVP Receptor V1a Antibody (721CT25.2.1): sc-517313
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
AVP Receptor V1a Double Nickase Plasmid (h) | sc-401691-NIC | 20 µg | $410.00 | |||
AVP Receptor V1a Double Nickase Plasmid (h2) | sc-401691-NIC-2 | 20 µg | $410.00 |
AVPR1A encodes the human arginine vasopressin receptor 1A (AVP Receptor V1a), a G protein–coupled receptor that primarily couples to Gq/11 to activate phospholipase Cβ, elevating intracellular Ca²⁺ and diacylglycerol to drive protein kinase C signaling. This receptor modulates vascular smooth muscle contraction, platelet function, hepatic glycogenolysis, and neuroendocrine signaling, integrating vasopressin responses across peripheral tissues and the central nervous system. AVPR1A-dependent pathways intersect with MAPK/ERK and immediate-early gene programs, linking receptor activation to context-dependent transcriptional and cellular responses. Dysregulated AVPR1A signaling or genetic variation has been investigated in cardiovascular and metabolic phenotypes as well as neurobehavioral traits, supporting its relevance for mechanistic studies of vasopressin-responsive pathways.
AVP Receptor V1a Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the AVPR1A locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within AVPR1A. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt AVPR1A function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of AVPR1A-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.